ClinicalTrials.gg
CompletedNCT03415230Updated Jan 31, 2019

Effect of Therapeutic Massage on Sleep Quality and Stress Levels in Women With Breast Cancer

An interventional study of Therapeutic massage and Sham massage in Sleep Disturbance and Anxiety, sponsored by Cyprus University of Technology. Completed at 1 site in Cyprus. Open to female participants aged 18 Years to 60 Years. Per ClinicalTrials.gov, last updated 2019-01-31.

Primary conditionAnxiety Disorders(the registry's first term)UnverifiedIs this wrong?The registry often attaches Anxiety Disorders to studies about something else, and this study's title and listed conditions do not name it. No better condition is named, so the registry's term is kept.

Sponsored by Cyprus University of Technology · Not applicable, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
40
Allocation
Randomized
Ages
18 Years to 60 Years
Sex
Female
01

Study summary

This is a randomized control trial to test the effectiveness of therapeutic massage on the sleep quality and the stress levels in women that have completed their treatment for breast cancer.

Read the detailed description

The period following the completion of treatment for breast cancer (but also for any other type of cancer as well) is once that is accompanied by an increased uncertainty. This can often trigger increased anxiety levels and sleep disturbances. This trial tests the effectiveness of therapeutic massage as a non pharmaceutical intervention that can increase the management of stress and sleep disturbances during this period of time.

02

Conditions studied

  • Sleep Disturbance
  • Anxiety

Browse trials for

03

In context

Anxiety Disorders Unverified

7,207 studies on the registry are indexed under Anxiety Disorders; 1,682 are open to participants now.

This study's enrollment of 40 is below the median of 80 across 6,062 interventional studies indexed under Anxiety Disorders.

Browse Anxiety Disorders studies →

Lead sponsor

Cyprus University of Technology is the lead sponsor of 27 studies on the registry; 3 are open to participants now.

Compared within Anxiety Disorders, the registry's first condition term, which may not be this study's main condition. Counted across the registry records on this site, refreshed daily. How we classify →

04

Who can participate

Ages eligible
18 Years to 60 Years
Sexes eligible
Female
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Women that completed their treatment
  • women experiencing insomnia
  • women experiencing anxiety
  • women that speak and understand Greek

Exclusion criteria

Exclusion Criteria:

  • allergy to essential oils
  • use of anticoagulants
  • presence of edema
  • presence of Varicose veins
05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Care provider)
Enrollment
40 participants (actual)

Study arms

  • Experimental
    Therapeutic massage

    Women will undertake sessions of therapeutic massage

    Other: Therapeutic massage

  • Sham comparator
    Sham massage

    Women will undertake sessions of sham massage

    Other: Sham massage

Interventions

  • OtherTherapeutic massage

    Massage therapy involves the administration of combinations of specific physical manipulations applied in a systematic way, with varying intensity, direction, rate, and rhythm, to the soft tissues of the body.

  • OtherSham massage

    Sham massage involves only light touch massage in a non systematic way

06

What researchers measure

Primary outcomes

  1. Sleep Disturbances (insomnia)

    Athens insomnia scale (The AIS is a self-assessment psychometric instrument designed for quantifying sleep difficulty based on the ICD-10 criteria. It consists of eight items: the first five pertain to sleep induction, awakenings during the night, final awakening, total sleep duration, and sleep quality; while the last three refer to well-being, functioning capacity, and sleepiness during the day). Each item of the AIS can be rated 0-3, (with 0 corresponding to no problem at all and 3 to very serious problem); thus, the total score ranges from 0 (absence of any sleep-related problem) to 24 (the most severe degree of insomnia).

    Time frame: Change from baseline total score at 4 weeks

Secondary outcomes

  1. Anxiety

    Hamilton Anxiety Rating Scale (HAM-A). The scale consists of 14 items. Each item is scored on a scale of 0 (not present) to 4 (severe), with a total score range of 0-56, where \<17 indicates mild severity, 18-24 mild to moderate severity and 25-30 moderate to severe.

    Time frame: Change from baseline total score at 4 weeks

07

Study locations

1 site
  • Oncology Centre
    Nicosia, 2006, Cyprus
08

References and documents

Individual participant data

Plan to share: Undecided — Demographic information can be shared

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Apr 2018 to primary completion in Dec 2018, 8 months.

Of 3,841 non-industry interventional studies with no phase under Anxiety Disorders, half reached primary completion within 12 months of starting (the median), counting those still running; a quarter within 5 and three quarters within 28. This study's 8 months is below that.

Counting every sponsor, half of 3,943 studies reached it within 12 months; a quarter within 5 and three quarters within 28.

How these figures are worked out, and which studies are left out of them.

Registered
Jan 9, 2018
First posted
Jan 30, 2018
StartActual
Apr 1, 2018
Primary completionActual
Dec 20, 2018
CompletionActual
Jan 9, 2019
Last update
Jan 31, 2019
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jan 31, 2019, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT03415230
Lead sponsor
Cyprus University of Technology
Collaborators
Cyprus Anticancer Society
Responsible party
Dr. Andreas Charalambous (Associate Professor, Cyprus University of Technology) — Principal investigator
First posted
Jan 30, 2018
Start date
Apr 1, 2018
Primary completion
Dec 20, 2018
Completion
Jan 9, 2019
Last update
Jan 31, 2019

Study contacts

Andreas Charalambous, PhD
principal investigator · Cyprus University of Technology

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jan 2019. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion